Ontario Brain Institute Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2013
NCT01769092
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Ontario Brain Institute | The Epilepsy Research Program of the Ontario Brain Institute

Active Ingredients

Drugs in Phase 3 Trials (3)

cannabis (1 trial)

fish oil (Omegavan) (1 trial)

safflower oil (1 trial)

Drugs in Phase 2 Trials (1)

sertraline (zoloft) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Drug Resistant Epilepsy (Phase 3)

Epilepsy (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4